The PACS Group, Inc. (NYSE: PACS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret them. As a healthcare holding company in the post-acute care and medical care facilities space, PACS uses SEC reports to describe its facility portfolio, credit arrangements, governance, and risk profile.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of PACS Group’s operations, financial condition, and risk factors. These filings also provide context on the company’s role as a holding company, the structure of its independent operating subsidiaries, and the separation between licensed healthcare providers and non-provider entities. AI-generated highlights can point out key sections on post-acute care operations, use of credit facilities, and lease obligations.
Current reports on Form 8-K are particularly important for PACS, given its history of restatements, credit agreement amendments, and NYSE listing updates. Recent 8-K filings have addressed topics such as forbearance and amendments under the company’s amended and restated credit agreement, events of default and related waivers, NYSE listing extensions tied to delayed SEC filings, and the completion of an independent Audit Committee investigation and related restatements. AI summaries can help users quickly understand the implications of these events.
Users can also access proxy materials such as the Definitive Proxy Statement on Schedule 14A, which outlines matters presented to stockholders at the annual meeting, including director elections, auditor ratification, and advisory votes on executive compensation. In addition, the filings page provides real-time updates from EDGAR and convenient access to other forms, such as notifications of late filings on Form 12b-25. Together, these documents offer a comprehensive view of PACS Group’s regulatory history, governance decisions, and financial reporting, with AI tools available to simplify and explain complex disclosures.
PACS Group, Inc. Chief Accounting Officer Michelle Renee Lewis reported selling 9,464 shares of common stock on October 28, 2026, at a weighted average price of $50.1231 per share, and 2,364 shares on October 29, 2026, at a weighted average price of $50.0351 per share. Both sales were effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.
PACS Group, Inc. Co-Founder, CEO & Chairman Jason Hulse Murray sold 6,899 shares of common stock at a weighted average price of $50.0977 per share on October 28, 2026, and 1,904 shares at a weighted average price of $50.0469 per share on October 29, 2026. Both sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026.
PACS Group, Inc. director and ten percent owner Mark Hancock sold 9,024 common shares on October 28, 2026, at a weighted average price of $50.1020 per share, and 4,280 common shares on October 29, 2026, at a weighted average price of $50.0236 per share. Both sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2026.
PACS Group, Inc. is named as issuer in Mark Hancock’s proposed sale of 4,280 common shares, with an aggregate market value of $214,101.01. The approximate sale date is October 29, 2026, and Citigroup Global Markets Inc. is listed as broker; NYSE is listed as the exchange. Acquisition details list 54,626,199 common shares acquired from the issuer at formation on March 1, 2023, for cash. Mark Darrell Hancock signs the notice.
PACS Group, Inc. is named as issuer in a Form 144 notice signed by Mark Darrell Hancock, identifying Mark Hancock as the person for whose account securities are to be sold. The notice lists a proposed sale of 9,024 common shares through Citigroup Global Markets Inc., with an aggregate market value of $452,120.45 and an approximate sale date of October 28, 2026. It lists 158,026,588 common shares outstanding and records prior sales of 144,318 shares on September 14, 2026, and 155,682 shares on September 15, 2026.
PACS Group, Inc. is the issuer named in a Rule 144 notice covering officer Michelle Renee Lewis’s proposed sale of 15,000 common shares through J.P. Morgan Securities LLC. The shares are listed with an aggregate market value of $717,750; the notice also lists 158,335,612 shares outstanding. The shares were acquired from the issuer through RSU vesting on April 15, 2026. The approximate sale date is October 28, 2026, and the remarks state the shares will be sold today or within three months from the notice date.
PACS Group, Inc. Co-Founder, CEO & Chairman Jason Hulse Murray sold 13,696 shares on October 22, 2026, at a weighted average price of $47.5475 per share. On October 23, he sold 22,722 shares at a weighted average price of $48.2084 and 46,195 shares at a weighted average price of $48.7885.
All three sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026. The weighted average prices reflected multiple transactions at prices ranging from $47.50 to $47.65, $47.50 to $48.495, and $48.50 to $49.105, respectively.
PACS Group, Inc. Co-Founder, CEO & Chairman Jason Hulse Murray reported selling 45,707 shares of common stock across October 19 through October 21, 2026. The sales were made under a Rule 10b5-1 trading plan adopted May 18, 2026. Reported weighted-average sale prices per share were $47.5677 for 1,620 shares on October 19, $47.6511 for 37,477 shares on October 20, and $47.6180 for 6,610 shares on October 21.
PACS Group, Inc. President & COO Joshua Jergensen sold 40,000 common shares on October 14, 2026, at a weighted average price of $44.5001 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 12, 2026. Shares were sold in multiple transactions at prices ranging from $44.005 to $44.91 per share; Jergensen reported direct holdings of 2,456,320 shares after the sale.
PACS Group, Inc.'s Co-Founder, CEO & Chairman, Jason Hulse Murray, sold 118,729 shares of common stock in six direct transactions from October 14 through October 16, 2026. The sales were made under a Rule 10b5-1 trading plan adopted May 18, 2026. The reported price was $45.0000 for 232 shares on October 14; weighted-average prices were $45.6117 for 4,633 shares, $46.7837 for 24,800 shares, $47.4916 for 77,540 shares, and $48.1052 for 3,062 shares on October 15; and $47.6100 for 8,462 shares on October 16.